Literature DB >> 22848040

Quality of life in childhood immune thrombocytopenia: international validation of the kids' ITP tools.

Robert J Klaassen1, Victor Blanchette, Tricia A Burke, Cindy Wakefield, John D Grainger, Gerhard Gaedicke, Arne Riedlinger, Gustavo Dufort, Estela Citrin, Yves Reguerre, Isabelle Pellier, Christine Curtis, Nancy L Young.   

Abstract

BACKGROUND: The Kids ITP Tools (KIT) is a disease-specific measure of health-related quality of life for children with immune thrombocytopenia (ITP). To facilitate use in international trials it has been cross-culturally adapted for France, Germany, the United Kingdom and Uruguay. This study assessed the validity and reliability of the translated KIT in comparison to generic quality of life measures.
METHODS: Children 2-18 years of age with ITP and their parents were recruited in France, Germany, the United Kingdom and Uruguay. Participants completed the KIT, PedsQL and KINDL. We examined the Pearson's correlation between these measures for our pooled sample and estimated the reliability over a 2-week time period. Findings were further explored by country.
RESULTS: A total of 127 families (81 children self-reported) participated. Mean child-reported scores were: KIT 74.3 (SD = 15.3), PedsQL 81.3 (SD = 13.0), and KINDL 70.5 (SD = 14.3). Corresponding mean parent proxy-reported scores were: 70.6 (SD = 18.1), 75.7 (SD = 16.8) and 72.3 (SD = 12.7), respectively. Correlation between KIT and the generic measures was consistent with our a priori hypothesis (PedsQL r = 0.54, KINDL r = 0.48, both P < 0.0001). Child KIT scores for newly diagnosed ITP patients were significantly lower than for chronic ITP patients (67.3 vs. 77.3; P = 0.005). There was a significant correlation (P < 0.001) between the child and parent proxy KIT scores (ICC = 0.52). Child KIT test-retest reliability was acceptable at 0.71.
CONCLUSIONS: The cross-culturally translated KIT is valid and reliable with acceptable correlation to the PedsQL and KINDL. There is a significant difference in child self-reported KIT scores between newly diagnosed and chronic ITP.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22848040     DOI: 10.1002/pbc.24257

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  9 in total

1.  Health-related quality of life in children with newly diagnosed immune thrombocytopenia.

Authors:  Katja M J Heitink-Pollé; Lotte Haverman; Kim V Annink; Sarah J Schep; Masja de Haas; Marrie C A Bruin
Journal:  Haematologica       Date:  2014-06-20       Impact factor: 9.941

2.  The child with immune thrombocytopenia: to treat or not to treat, is that still the question?

Authors:  Nichola Cooper; Douglas B Cines
Journal:  Haematologica       Date:  2019-11       Impact factor: 9.941

3.  IVMP+IVIG raises platelet counts faster than IVIG alone: results of a randomized, blinded trial in childhood ITP.

Authors:  Manuel Carcao; Mariana Silva; Michele David; Robert J Klaassen; MacGregor Steele; Victoria Price; Cindy Wakefield; Lussia Kim; Derek Stephens; Victor S Blanchette
Journal:  Blood Adv       Date:  2020-04-14

4.  Standardized clinical assessment and management plans (SCAMPs): perspectives on a new method to understand treatment decisions and outcomes in immune thrombocytopenia.

Authors:  Rachael F Grace
Journal:  Semin Hematol       Date:  2013-01       Impact factor: 3.851

Review 5.  Spotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy.

Authors:  David Buchbinder; Diane Nugent; Loan Hsieh
Journal:  Drug Des Devel Ther       Date:  2017-03-30       Impact factor: 4.162

Review 6.  Immune Thrombocytopenia (ITP): Current Limitations in Patient Management.

Authors:  Deirdra R Terrell; Cindy E Neunert; Nichola Cooper; Katja M Heitink-Pollé; Caroline Kruse; Paul Imbach; Thomas Kühne; Waleed Ghanima
Journal:  Medicina (Kaunas)       Date:  2020-11-30       Impact factor: 2.430

7.  Evaluation of health related quality of life in children with immune thrombocytopenia with the PedsQL™ 4.0 Generic Core Scales: a study on behalf of the pays de Loire pediatric hematology network.

Authors:  Marion Strullu; Josué Rakotonjanahary; Eliane Tarral; Christophe Savagner; Caroline Thomas; Françoise Méchinaud; Yves Reguerre; Sylvaine Poignant; Arnaud Boutet; Joachim Bassil; Dominique Médinger; Emmanuel Quemener; Nancy L Young; Petronela Rachieru; Robert J Klaassen; Isabelle Pellier
Journal:  Health Qual Life Outcomes       Date:  2013-11-13       Impact factor: 3.186

8.  A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Romiplostim on Health-Related Quality of Life in Children with Primary Immune Thrombocytopenia and Associated Burden in Their Parents.

Authors:  Susan D Mathias; Xiaoyan Li; Melissa Eisen; Nancy Carpenter; Ross D Crosby; Victor S Blanchette
Journal:  Pediatr Blood Cancer       Date:  2016-04-01       Impact factor: 3.167

9.  Health-related quality of life in children with chronic immune thrombocytopenia in China.

Authors:  Heng Zhang; Li Wang; Meijie Quan; Jie Huang; Peng Wu; Qin Lu; Yongjun Fang
Journal:  Health Qual Life Outcomes       Date:  2016-03-15       Impact factor: 3.186

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.